In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles

Jaehong Key, Christy Cooper, Ah Young Kim, Deepika Dhawan, Deborah W. Knapp, Kwangmeyung Kim, Jae Hyung Park, Kuiwon Choi, Ick Chan Kwon, Kinam Park, James F. Leary

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

One difficulty of diagnosing and treating cancer is that it is very challenging to detect cancers in the early stages before metastasis occurs. A variety of imaging modalities needs to be used from non-invasive, moderate resolution modalities, such as magnetic resonance imaging (MRI) to very high-resolution (e.g. fluorescence) imaging that can help guide surgeons during a surgical operation. While MRI can have relatively high resolution and deep penetration to visualize soft tissues, low sensitivity of MRI frequently requires tumor imaging agents to enhance the MRI contrast at the tumor site. At the other end of the resolution spectrum, near infrared fluorescence (NIRF) imaging has very high sensitivity but frequently cannot be utilized for initial human in vivo imaging due to its very limited penetration depth. To combine the advantages of each imaging modality we have constructed MRI and NIRF dual-modality nanoparticles using glycol chitosan, Cy5.5, and superparamagnetic iron oxide nanoparticles (SPIOs). We have demonstrated these advantages for dual-modality, in vivo tumor imaging in mice. Our studies suggest the potential use of NIRF and MR dual modality imaging for human cancer diagnosis.

Original languageEnglish
Pages (from-to)249-255
Number of pages7
JournalJournal of Controlled Release
Volume163
Issue number2
DOIs
Publication statusPublished - 2012 Oct 28

Fingerprint

Nanoparticles
Fluorescence
Magnetic Resonance Imaging
Neoplasms
Optical Imaging
glycol-chitosan
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Key, J., Cooper, C., Kim, A. Y., Dhawan, D., Knapp, D. W., Kim, K., ... Leary, J. F. (2012). In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles. Journal of Controlled Release, 163(2), 249-255. https://doi.org/10.1016/j.jconrel.2012.07.038
Key, Jaehong ; Cooper, Christy ; Kim, Ah Young ; Dhawan, Deepika ; Knapp, Deborah W. ; Kim, Kwangmeyung ; Park, Jae Hyung ; Choi, Kuiwon ; Kwon, Ick Chan ; Park, Kinam ; Leary, James F. / In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles. In: Journal of Controlled Release. 2012 ; Vol. 163, No. 2. pp. 249-255.
@article{2bef6fa44090443e96fb6d9a86557115,
title = "In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles",
abstract = "One difficulty of diagnosing and treating cancer is that it is very challenging to detect cancers in the early stages before metastasis occurs. A variety of imaging modalities needs to be used from non-invasive, moderate resolution modalities, such as magnetic resonance imaging (MRI) to very high-resolution (e.g. fluorescence) imaging that can help guide surgeons during a surgical operation. While MRI can have relatively high resolution and deep penetration to visualize soft tissues, low sensitivity of MRI frequently requires tumor imaging agents to enhance the MRI contrast at the tumor site. At the other end of the resolution spectrum, near infrared fluorescence (NIRF) imaging has very high sensitivity but frequently cannot be utilized for initial human in vivo imaging due to its very limited penetration depth. To combine the advantages of each imaging modality we have constructed MRI and NIRF dual-modality nanoparticles using glycol chitosan, Cy5.5, and superparamagnetic iron oxide nanoparticles (SPIOs). We have demonstrated these advantages for dual-modality, in vivo tumor imaging in mice. Our studies suggest the potential use of NIRF and MR dual modality imaging for human cancer diagnosis.",
author = "Jaehong Key and Christy Cooper and Kim, {Ah Young} and Deepika Dhawan and Knapp, {Deborah W.} and Kwangmeyung Kim and Park, {Jae Hyung} and Kuiwon Choi and Kwon, {Ick Chan} and Kinam Park and Leary, {James F.}",
year = "2012",
month = "10",
day = "28",
doi = "10.1016/j.jconrel.2012.07.038",
language = "English",
volume = "163",
pages = "249--255",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

Key, J, Cooper, C, Kim, AY, Dhawan, D, Knapp, DW, Kim, K, Park, JH, Choi, K, Kwon, IC, Park, K & Leary, JF 2012, 'In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles', Journal of Controlled Release, vol. 163, no. 2, pp. 249-255. https://doi.org/10.1016/j.jconrel.2012.07.038

In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles. / Key, Jaehong; Cooper, Christy; Kim, Ah Young; Dhawan, Deepika; Knapp, Deborah W.; Kim, Kwangmeyung; Park, Jae Hyung; Choi, Kuiwon; Kwon, Ick Chan; Park, Kinam; Leary, James F.

In: Journal of Controlled Release, Vol. 163, No. 2, 28.10.2012, p. 249-255.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles

AU - Key, Jaehong

AU - Cooper, Christy

AU - Kim, Ah Young

AU - Dhawan, Deepika

AU - Knapp, Deborah W.

AU - Kim, Kwangmeyung

AU - Park, Jae Hyung

AU - Choi, Kuiwon

AU - Kwon, Ick Chan

AU - Park, Kinam

AU - Leary, James F.

PY - 2012/10/28

Y1 - 2012/10/28

N2 - One difficulty of diagnosing and treating cancer is that it is very challenging to detect cancers in the early stages before metastasis occurs. A variety of imaging modalities needs to be used from non-invasive, moderate resolution modalities, such as magnetic resonance imaging (MRI) to very high-resolution (e.g. fluorescence) imaging that can help guide surgeons during a surgical operation. While MRI can have relatively high resolution and deep penetration to visualize soft tissues, low sensitivity of MRI frequently requires tumor imaging agents to enhance the MRI contrast at the tumor site. At the other end of the resolution spectrum, near infrared fluorescence (NIRF) imaging has very high sensitivity but frequently cannot be utilized for initial human in vivo imaging due to its very limited penetration depth. To combine the advantages of each imaging modality we have constructed MRI and NIRF dual-modality nanoparticles using glycol chitosan, Cy5.5, and superparamagnetic iron oxide nanoparticles (SPIOs). We have demonstrated these advantages for dual-modality, in vivo tumor imaging in mice. Our studies suggest the potential use of NIRF and MR dual modality imaging for human cancer diagnosis.

AB - One difficulty of diagnosing and treating cancer is that it is very challenging to detect cancers in the early stages before metastasis occurs. A variety of imaging modalities needs to be used from non-invasive, moderate resolution modalities, such as magnetic resonance imaging (MRI) to very high-resolution (e.g. fluorescence) imaging that can help guide surgeons during a surgical operation. While MRI can have relatively high resolution and deep penetration to visualize soft tissues, low sensitivity of MRI frequently requires tumor imaging agents to enhance the MRI contrast at the tumor site. At the other end of the resolution spectrum, near infrared fluorescence (NIRF) imaging has very high sensitivity but frequently cannot be utilized for initial human in vivo imaging due to its very limited penetration depth. To combine the advantages of each imaging modality we have constructed MRI and NIRF dual-modality nanoparticles using glycol chitosan, Cy5.5, and superparamagnetic iron oxide nanoparticles (SPIOs). We have demonstrated these advantages for dual-modality, in vivo tumor imaging in mice. Our studies suggest the potential use of NIRF and MR dual modality imaging for human cancer diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=84867632481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867632481&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2012.07.038

DO - 10.1016/j.jconrel.2012.07.038

M3 - Article

C2 - 22902594

AN - SCOPUS:84867632481

VL - 163

SP - 249

EP - 255

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -